Chapter

Technical Aspects of Toxicological Immunohistochemistry

pp 73-94

Date:

Immunohistochemistry in the Study of Cancer Biomarkers for Oncology Drug Development

  • Fang JiangAffiliated withCancer Discovery, Global Pharmaceutical Research and Development, Abbott Laboratories Email author 
  • , Evelyn M. McKeeganAffiliated withCancer Discovery, Global Pharmaceutical Research and Development, Abbott Laboratories

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Immunohistochemistry (IHC) assays can identify tumor biomarkers and provide valuable information for oncology drug development. This chapter describes the basic IHC assay step by step to identify target proteins and assess protein expression levels and subcellular localization. The steps are tissue preparation, fixation, selection of antibody and controls, detection system, counterstain, coverslip, score, and troubleshooting. The chapter also discusses the use of IHC assays in cancer biomarker studies, in particular the application of a multi-fluorophore labeling technique to study tumor vasculature in preclinical human xenograft tumor models for antiangiogenic drug development, and the use of an immunocytochemistry (ICC) assay on circulating tumor cell isolated from clinical samples. The study data demonstrate that IHC assays provide important information for cancer biomarker studies, illuminating the mechanisms of action for oncology drugs. IHC arrays are indispensable tools in histogenic assessment and biomarker development.

Keywords

Immunohistochemistry Angiogenesis Tumor vascular measurement Circulating tumor cell Antigen retrieval Cancer biomarker